Restless Legs Syndrome Market - Research Report, 2023by PSMR Industry Web Marketing
legs syndrome increases at night when the patient is at rest. RLS are common in
both, male and female; however the disease has its highest impact on woman who
are elderly or in some cases woman with the age 35 to 50 years. Some of the
most common symptoms of the restless legs syndrome are continue itching and
pain in the legs, and unusual sleep pattern. The restless legs syndrome affects
the quality of life of the person suffering from the disease.
treatment of this disease is not present till now. However the available drug
in the market helps in the indicative treatment of the disease. Some of the
drug in the restless legs syndrome market such as sulfonamide by safinamide
by Newron Pharmaceuticals reduces the symptoms by novel action such as potent,
reversible and selective inhibition of MAO-B, without disturbing the MAO-A and
dopamine uptake. This enhances the glutamate release and dopaminergic function
of the patients; it also reduces the dopamine degradation. One other drug:
SER-214 manufacture by Serina is used widely in the restless legs syndrome
treatment; it uses a water-soluble polymer poly (2-alkyloxazoline)-based drug
delivery technology this drug can be combined with the polymer and transported
to the patients.
Created on Sep 14th 2017 17:51. Viewed 594 times.